Research Overview
Chemistry of the modification
Capping the N-terminus with an acetyl group and amidating the C-terminus removes the two charged ends that exopeptidases recognize. The result is a neutral-terminus peptide with the same Thr-Lys-Pro-Arg tuftsin motif and the same Pro-Gly-Pro tail. C-terminal amidation in particular mirrors a post-translational modification found on many endogenous neuropeptides, which is one reason it is a standard tool in analog design.
Stability-focused experiments
- Time-course incubation in plasma or tissue homogenate with LC-MS quantification of intact peptide
- Enzymatic challenge assays against isolated aminopeptidases and carboxypeptidases
- Formulation studies comparing solution stability and aggregation behavior across pH and temperature
Behavioral and immune context inherited from Selank
The parent peptide has been examined in rodent anxiety-like paradigms with reported correlates in GABA-A receptor subunit expression, monoamine turnover and enkephalin-degrading enzyme activity, and separately in cytokine and lymphocyte studies reflecting tuftsin's immune origin. Investigators working with the protected analog generally run these same endpoints to ask whether terminal protection changes the observed profile.
Evidence status
Analytical confirmation
The two terminal modifications shift the molecular ion relative to unmodified Selank, so mass spectrometry provides a direct check that both the acetyl cap and the C-terminal amide are present. When the protected analog and its parent are compared in the same panel, note net peptide content and counterion from each certificate of analysis; ignoring those figures is a common source of apparent potency differences that are really concentration errors.
